Frontiers’ Cell Metabolism Section Anchors Research on Disease Mechanisms at the Cellular Level

The Cell Metabolism, Proliferation and Disease section at Frontiers is built around a simple editorial premise: keep mechanistic work on cell growth, metabolism, and disease biology visible to a broad research audience. The page presents the section as part of Frontiers in Cell and Developmental Biology, with a submission portal, editorial board links, and a running catalog of articles that fall within this scientific niche. It is not a clinical trial registry or a patient-facing bulletin. It is a publication hub designed to move bench science into circulation.

The emphasis is unmistakably on cellular processes that shape pathology. Metabolic control, proliferation, senescence, and disease development sit close together in this framing because they often converge in the same tissue and the same disease state. A dysregulated cell does not merely divide too fast or too slowly; it also rewires fuel use, stress signaling, and tissue repair. In practical research terms, that means the section favors studies that connect molecular events to a disease phenotype rather than describing isolated pathways in a vacuum.

Editorial Leadership Gives the Section Its Scientific Borders

The section lists Philipp Kaldis of Lund University in Sweden as Specialty Chief Editor. Three Associate Editors are named as well: Deepak Adhikari of Monash University in Australia, Marti Aldea of the Spanish National Research Council in Barcelona, and Eiman Aleem of London South Bank University in the United Kingdom. Those affiliations matter because editorial leadership often signals how a journal section interprets its own scope. Here, the footprint is international and centered on basic and translational cell biology rather than a single organ system or disease category.

The page also frames the section as part of a broader Frontiers publishing model that emphasizes peer review, research integrity, and editorial oversight. The wording on the page points to AI-enhanced quality checks and proactive fraud detection, a reminder that even in mechanistic biology, editorial trust is now part of the scientific workflow. For authors, the result is a structured route from manuscript preparation to external review and publication. For readers, it creates a curated stream of papers that have passed through that system.

Research metabolism is no longer a side topic in cell biology.

Recent Articles Point to the Section’s Core Scientific Interests

The most recent items visible on the page make the section’s thematic center easy to see. One listed review is titled “Cellular senescence and benign prostatic hyperplasia: the pathological role of the senescence-associated secretory phenotype and the translational potential of senolytics.” Another is a brief research report on “Dynamics of primary ciliated cells in human lung development, adult homeostasis, and COPD.” Even without extra detail, those titles sketch the section’s range: senescence biology on one side, cilia and lung homeostasis on the other.

Both topics sit squarely inside disease-oriented cell biology. Senescent cells can stop dividing while remaining metabolically active, and their secretory behavior is often implicated in persistent tissue dysfunction. In benign prostatic hyperplasia, that biology is especially relevant because abnormal growth and chronic tissue remodeling overlap. Primary cilia, by contrast, act as sensory and signaling structures, and changes in their dynamics can alter how tissue interprets developmental and homeostatic cues. In chronic obstructive pulmonary disease, that line of inquiry becomes especially relevant because airway structure and repair are central to the disease process.

The section page does not present outcomes, effect sizes, or patient-level data. It does something more basic and more structural: it identifies the research questions that belong in this venue. That matters because the front end of scientific publication is often where fields define themselves. Which mechanisms are treated as central? Which tissues count as relevant? Which disease phenotypes deserve a molecular explanation? The answer, in this case, leans toward cellular aging, tissue homeostasis, proliferative control, and the molecular machinery that links them to disease.

What the Section Platform Signals for Translational Biology

A section like this functions as more than a folder of articles. It is a filter for ideas that can travel from molecular observation to disease interpretation. The presence of senescence, senolytics, cilia, lung development, and COPD on the same page suggests a common editorial thread: biology becomes more useful when it is tied to phenotype, repair, or degeneration. That is the core promise of translational cell biology, even when the work remains at the level of cells and tissues rather than patients.

For investigators, the page offers a clear message about what belongs here. Studies should speak to how cells proliferate, pause, age, communicate, or fail in disease. For clinicians reading across disciplines, the value is indirect but real. Mechanistic papers published in a section like this often provide the conceptual scaffolding for future diagnostic markers, therapeutic targets, or explanations for why a disease behaves the way it does in a given organ.

The current page leaves one thing unresolved: the pace at which these mechanistic themes will convert into clinically actionable findings. It lists the architecture of the section and the topics under review, but not the downstream impact of each paper. The next readouts will have to come from the individual studies themselves, where the actual biological signal will be measured against the noise of complex disease.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Frontiers in Immunology.